What diseases is Sotoracib used to treat?

Sotorasib is a targeted drug targeting KRAS G12C gene mutations. It is mainly used to treat non-small cell lung cancer (NSCLC), especially those with advanced or recurrent patients with KRAS G12C mutations. KRASgene mutations are common in a variety of tumors, and KRAS G12C mutation is a specific type of mutation of this gene, which often occurs in patients with non-small cell lung cancer, accounting for about 13% to 15% of KRAS mutation cases in non-small cell lung cancer.

In the past, KRASmutations were considered"untargetable"gene mutations because the structural properties of the KRAS protein make it difficult to directly inhibit it with drugs. However, with the advancement of science, sotoracib, as the first targeted drug targeting the KRAS G12C mutation, has successfully demonstrated the ability to inhibit tumor growth in clinical trials. By binding to the KRAS G12C mutant protein, sotoracib prevents the activation of the KRAS signaling pathway, ultimately achieving the effect of inhibiting tumor proliferation.

The primary indication for sotoraxib is in patients with KRAS G12Cmutation-positive non-small cell lung cancer who have received at least one systemic therapy. In such patients, traditional therapies such as chemotherapy and immunotherapy have limited effectiveness, and the emergence of sotorasiib provides them with new options. Clinical trial results show that sotoraxib can significantly prolong progression-free survival (PFS) and achieve tumor shrinkage in some patients. In addition, sotoracib showed good tolerability in clinical trials, and patients experienced relatively mild adverse reactions, which also increases its application value in this indication.

In addition to non-small cell lung cancer, KRAS G12C mutations have been found in other cancers, such as colorectal and pancreatic cancer. Therefore, the application potential of sotoracib may not be limited to lung cancer, and may be used in more applications in the futureKRAS G12CExpand its indications in mutation-positive tumors to help more patients.